Breast Cancer, Metastatic   

Questions discussed in this category


In patients with prior perioperative immunotherapy with early relapse, would re-introduction of immunotherapy be reasonable with high TMB? 

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

The FDA recently approved trastuzumab deruxtecan (T-DXd) in the second line setting. Given the results of DESTINY-Breast03, what is now the role of TD...

Would you consider definitive local therapy (surgery, radiation?) if she achieved a good response to initial systemic therapy?

Which regimen is preferred in second line for these patients? What is the efficacy of TDXd vs tucatinib in CNS metastases?    

Would you obtain baseline PFT on all patients or only selected high risk patients? Would you repeat PFTs regularly or only if clinically symptomatic?&...

Given strong TDXd efficacy in these patients is there a role to use it earlier than 2nd line? How does prior Her2-directed and/or taxane therapy...

Patient is young. Bilirubin normalizes when tucatinib is held, but again increases to grade 2 when it is restarted. Evaluation for hemolysis was negat...

Although grade 3 toxicity rates were low, ~10.5% experience some degree of ILD, are there strategies to reduce risk before treatment starts? Are ther...

In which scenarios would you consider a parp inhibitor as the first line treatment of choice? 

Many of the patients on ASCENT trial were heavily pre-treated and require growth factors. With the day 1,8 treatment cycle, is there a way to minimize...

Given seemingly improved efficacy in ASCENT patients who had less prior treatment, would you consider use after only one prior agent rather than two? ...

Are there specific patient cohorts in whom you will more preferentially use sacituzumab govitecan? Can data from ASCENT be applied to patients with C...

The patient previously received endocrine therapy alone and in combination with CDK 4/6 inhibitor. She does not have any targetable mutations on NGS. ...

To what degree do you factor in patient preference when choosing among available treatments? Are there features of each regimen that you emphasize in ...

What about a higher penetrance PV such as PALB2? See JCO OGR 8/2021 by @Mark E. Robson discussing management of non-BRCA pathogenic va...

The patient is treatment naïve and asymptomatic. She also has disease in the body (bone and liver metastases). 

The patient initially received definitive therapy with AC-T and RT to the breast as well as RT to a solitary bone lesion. She has been on AI for the l...

The patient has extensive liver metastases and a high bilirubin. She has not received any prior systemic therapy in the metastatic setting. 

The patient was started on chemoimmunotherapy 3 years ago. Recent scans show small treated brain metastases (s/p RT several years ago) and no disease ...

Patient with T2N1 disease and isolated liver metastases. Axilla and liver completely responded to chemo + IO, but limited residual breast enhancement ...

Patient is on fulvestrant+CDK 4/6 inhibitor and with NED for 5 years. In which cases would you consider stopping CDK 4/6 inhibitor? 


Papers discussed in this category


The New England journal of medicine, 2012-01-12

The New England journal of medicine, 2012-11-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-10

N Engl J Med,

N Engl J Med, 2019 Dec 11

J Clin Oncol, 2020 Oct 29

Semin Cell Dev Biol, 2011 Jul 28

Nat Med, 2019 Sep 30

Cancer Treat Rev, 2022 Mar 12

N. Engl. J. Med., 2019 Dec 11

J Clin Oncol, 2020 May 29

Cancer Manag Res, 2012 Jun 13

Ann Oncol, 2007 Feb 13

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-12-10

Lancet Oncol, 2020 Aug 27

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-20

N Engl J Med, 2021 Apr 22

N Engl J Med,

Cancer Discov, 2021 Aug 17

Ann Oncol, 2021 Mar 16

Annals of oncology : official journal of the European Society for Medical Oncology, 2001-09

Cochrane Database Syst Rev, 2021 May 26

J. Clin. Oncol., 2020 Sep 20

Clin Cancer Res, 2020 Jan 1

JAMA Oncol, 2019 Sep 29

J Clin Oncol, 2021 Mar 26

The Lancet. Oncology, 2017-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-10-10

JAMA Oncol,

Breast Cancer Res Treat, 2018 Jul 04

Eur J Haematol, 2021 Feb 18

Br J Cancer, 2021 Jan 21

Clin Cancer Res, 2022 Jan 19

JCO Precis Oncol, 2019 Nov 15

The Lancet. Oncology, 2019-06

J Clin Oncol, 2020 Feb 14

N. Engl. J. Med., 2017 Jun 04

The New England journal of medicine, 2018-08-23

Breast Cancer Res Treat, 2016 Feb 18

Mol Cancer Ther, 2018 Mar 28

Eur J Cancer, 2014 Aug 12

J Clin Oncol, 2022 Jan 07

Oncotarget,

N. Engl. J. Med.,

N Engl J Med,

N Engl J Med, 2022 Jun 05

J Natl Compr Canc Netw, 2021 Mar 24

J Clin Oncol, 2019 Nov 04

N Engl J Med, 2018 Oct 20

Cancer Discov, 2020 Nov 02

Ann Oncol, 2021 Jul 01